237 related articles for article (PubMed ID: 19364953)
1. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
Sartor O
J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
[No Abstract] [Full Text] [Related]
2. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
3. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
4. [New perspectives in the drug therapy of hormone-resistant prostate cancer].
Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM
Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118
[No Abstract] [Full Text] [Related]
5. Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer.
Sartor O
Asian J Androl; 2011 May; 13(3):366-8. PubMed ID: 21499278
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic agents in prostate cancer: an enigma.
Yagoda A
Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617
[No Abstract] [Full Text] [Related]
7. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
Berdah JF
Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
[No Abstract] [Full Text] [Related]
8. [New drug treatment possibilities in castration resistant prostate carcinoma].
Meisel A; Stenner F
Praxis (Bern 1994); 2012 Sep; 101(18):1143-9; quiz 1150-1. PubMed ID: 22945814
[No Abstract] [Full Text] [Related]
9. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate].
Nogueira March JL; Ojea A; Jamardo D; Díez E; Figueiredo L
Arch Esp Urol; 1985; 38(1):28-34. PubMed ID: 4039554
[No Abstract] [Full Text] [Related]
10. In focus: prostate cancer.
Clin Adv Hematol Oncol; 2003 May; 1(5):271. PubMed ID: 16235417
[No Abstract] [Full Text] [Related]
11. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
Gardiner RA; Sweeney C; Tilley WD
Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
[No Abstract] [Full Text] [Related]
12. Long-term remission of metastatic small cell carcinoma of the prostate.
Ciszewski A; Shackleton D; Beer TM
Urology; 2008 Mar; 71(3):546.e3-4. PubMed ID: 18342209
[TBL] [Abstract][Full Text] [Related]
13. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced prostate cancer: 25 years later.
Logothetis CJ; Millikan R
J Clin Oncol; 2008 May; 26(15):2423-4. PubMed ID: 18487561
[No Abstract] [Full Text] [Related]
15. The management of hormone-relapsed prostate cancer.
Parkinson RW; Austin RH; Parr NJ
BJU Int; 2004 May; 93(7):1115. PubMed ID: 15142178
[No Abstract] [Full Text] [Related]
16. Chemotherapy of solid tumors.
Petersen M; Taylor JD
Med J Aust; 1978 Mar; 1(6):340. PubMed ID: 661705
[No Abstract] [Full Text] [Related]
17. Radium-223: the newest option in metastatic castration-resistant prostate cancer.
Sartor O
Clin Adv Hematol Oncol; 2013 Dec; 11(12):801-3. PubMed ID: 24893286
[No Abstract] [Full Text] [Related]
18. Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer.
Festuccia C; Negri-Cesi P; Gravina GL
Curr Drug Targets; 2016; 17(3):254-6. PubMed ID: 26876024
[No Abstract] [Full Text] [Related]
19. Abiraterone and increased survival in metastatic prostate cancer.
Parker C; Sartor O
N Engl J Med; 2011 Aug; 365(8):767. PubMed ID: 21864180
[No Abstract] [Full Text] [Related]
20. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
